Commonly
Asked Questions About The National Vaccine Injury Compensation Program
updated 12/18/2002
-
What is the National Vaccine Injury Compensation Program (VICP)?
- What
vaccines are covered?
- How
are new vaccines added for coverage under the VICP?
- Who
may file a claim?
- What
is the time frame in which to file a claim?
- Whom
can I contact to get more information about the VICP?
- How
is the VICP funded?
- How
does the VICP work?
- How
is eligibility for compensation determined?
- What
is the amount of an award under the VICP?
-
How does the VICP protect vaccine administrators and vaccine manufacturers?
-
Under what circumstances may a vaccine administrator or manufacturer
be sued?
-
Have there been changes to the Vaccine Injury Table?
-
What documentation are vaccine administrators required to keep?
-
What adverse events are health care providers required to report?
-
How many petitions have been filed under the VICP? Of those petitions
filed, how many have been awarded compensation? How much money has been spent
on compensation awards?
- If
I believe that the thimerosal (mercury) in a vaccine caused an injury or death,
can I file a claim with the VICP?
-
Where can I get information about anthrax or smallpox vaccines?
1.
What is the National Vaccine Injury Compensation Program (VICP)? The
National Childhood Vaccine Injury Act of 1986, as amended, (the Act) established
the VICP. The VICP went into effect on October 1, 1988 and is
a Federal "no-fault" system designed to compensate individuals or families
of individuals, who have been injured by covered childhood vaccines, whether administered
in the private or public sector. 2.
What vaccines are covered? Diphtheria,
tetanus, pertussis (DTP, DTaP, DT, TT, or Td), measles,
mumps, rubella (MMR or any components), polio (OPV or IPV), hepatitis
B, Haemophilus influenzae type b (Hib), varicella (chicken pox), rotavirus
and pneumococcal conjugate vaccines. Eight years' retroactive coverage
is provided for any vaccine or vaccine-related adverse event added for coverage
under the VICP. The
only live, oral, rhesus-based rotavirus vaccine licensed in the U.S., which was
routinely distributed beginning on October 1, 1998, was withdrawn from the market
on October 15, 1999, and is no longer being administered in the U.S. Because the
Secretary of Health and Human Services determined that a causal link existed between
this vaccine and the injury of intussusception, the Secretary modified the Vaccine
Injury Table (the Table) to add the injury of intussusception. Specifically,
effective as of August 26, 2002, the Secretary added vaccines containing live,
oral, rhesus-based rotavirus as a separate category to the Table, with an associated
injury of intussusception. Prior to this date, the Table already contained the
general category of rotavirus vaccines, with no associated Table injury. The new
Table injury of intussusception applies to all cases in which the injury occurred
within 30 days of the administration of the vaccine, provided that the rotavirus
vaccine was administered on or before August 26, 2002. Under
current law, petitioners may be eligible for compensation for vaccine-related
intussusceptions if the condition: (i) had residual effects or complications lasting
for more than 6 months; (ii) resulted in inpatient hospitalization and surgery;
or (iii) resulted in death. Petitioners
wishing to file claims relating to injuries (or deaths) thought to be related
to a rotavirus vaccine must generally comply with the statute of limitations contained
at 42 U.S.C. 300aa-16 (which provides that injury claims must be filed within
36 months of the date of the first symptom or manifestation of the onset or significant
aggravation of the injury). If the addition of the Table injury of intussusception
will significantly increase a petitioner's likelihood of obtaining compensation
with the VICP, a petitioner is also entitled to file a claim within 2 years of
the effective date of the Table change (August 26, 2002), so long as the underlying
vaccine-related injury or death occurred within an 8-year period before that date.
3. How are new
vaccines added for coverage under the VICP? On
March 24, 1997, a final rule was published which, in part, provided for the "automatic"
addition of future vaccines recommended by the Centers for Disease Control and
Prevention (CDC) for routine administration to children. However, Congress will
still need to set an appropriate excise tax on any new vaccines recommended by
CDC before those vaccines are effectively covered under the Vaccine Injury Compensation
Program. Under the current statutory language, 8 years' retroactive coverage will
be provided for those claiming injury or death resulting from a vaccine or vaccine-related
adverse event newly added to the VICP. 4.
Who may file a claim? Any
injured individual or a parent, legal guardian, or trustee of an injured child
or an incapacitated person may file a claim. A claim may be made for any injury
or death thought to be a result of a covered vaccine. These injuries may include,
but are not limited to: anaphylaxis, paralytic polio, and encephalopathy.
5. What
is the time frame in which to file a claim? For
claims resulting from a vaccine administered on or after October 1, 1988, the
following restrictions apply: a.
In the case of an injury, the effects must have continued at least 6 months after
vaccine administration or the injury must have resulted in inpatient hospitalization
and surgical intervention and the claim must be filed within 36 months after the
first symptoms appeared. b.
In the case of a death, the claim must be filed within 24 months of the death
and within 48 months after the onset of the vaccine-related injury from which
the death occurred.
As
of February 1, 1991, the time has expired for filing claims for injuries or deaths
resulting from vaccines administered prior to October 1, 1988. Any claims filed
for that time period are subject to dismissal by the U.S. Court of Federal Claims
(the Court).
6.
Whom can I contact to get more information about the VICP?
- This Web site (http://www.hrsa.gov/osp/vicp)
-
The toll-free number for the National Vaccine Injury Compensation Program
is
1-800-338-2382 to obtain an information packet detailing how to
file a claim, criteria for eligibility, and the documentation required. For further
information write to: National
Vaccine Injury Compensation Program Parklawn Building, Room 11C-26 5600
Fishers Lane Rockville, Maryland 20857 -
For information on the rules of the U.S. Court of Federal Claims, including
requirements for filing a petition, go to ttp://www.uscfc.uscourts.gov/osmPage.htm,
call 1-202-219-9657 or write to:
U.S.
Court of Federal Claims 717 Madison Place, N.W. Washington, D.C. 20005
7. How is the VICP
funded? Funding
of vaccine claims depends on the date of vaccination:
- For vaccines administered
prior to October 1, 1988, awards are compensated from Federal tax dollars
allocated by Congress at $110 million per year.
-
For vaccines administered on or after October 1, 1988, awards are paid
from the Vaccine Injury Compensation Trust Fund, funded from an excise tax of
$.75 on every dose of covered vaccine that is purchased.
8. How does the VICP
work? The
VICP is administered jointly by the U.S. Court of Federal Claims (the Court),
the Department of Health and Human Services (HHS), and the Department of Justice
(DOJ). The process is as follows: -
An individual claiming injury or death from a vaccine files a petition for compensation
with the Court;
-
A physician at the Division of Vaccine Injury Compensation, HHS, reviews each
petition to determine whether it meets the criteria for compensation. This recommendation
is provided to the Court through a report filed by the DOJ, although it is not
binding.
- The
HHS position is represented by an attorney from the DOJ in hearings before a "special
master" who makes the initial decision for compensation under the VICP. A
special master is an attorney appointed by the judges of the Court.
-
Decisions may be appealed to the Court and then to the Federal Circuit Court of
Appeals.
9.
How is eligibility for compensation determined? There
are three means to qualify for compensation: - A
petitioner must show that an injury found on the Vaccine Injury
Table (the Table) occurred; or
-
A petitioner must prove that the vaccine caused the condition; or
-
A petitioner must prove that the vaccine significantly aggravated a pre-existing
condition.
The
Table lists specific injuries or conditions and the time frames in which they
must occur after vaccine administration. The Table is a legal mechanism for defining
complex medical conditions and allows a statutory "presumption of causation."
It is much easier to demonstrate a "Table Injury" than to prove that
the vaccine caused the condition, and most claims allege that a Table Injury occurred.
Compensation is not awarded, however, if the Court determines that the injury
or death was due to a cause unrelated to the vaccine, even if it was a Table Injury. In
contrast to civil liability suits, hearings to determine eligibility under the
VICP usually last only 1 or 2 days. A case found eligible for compensation is
scheduled for a hearing to assess the amount of compensation. Most claims found
to be noncompensable receive awards for attorney's fees and costs.
10. What is the amount
of an award under the VICP? Awards
to the estate in a vaccine-related death are limited to $250,000 plus attorney's
fees and costs. Awards to individuals with an injury judged to be vaccine-related
have averaged $824,463. There is no limitation on the amount of an award in a
vaccine-related injury; however, the law does contain certain restrictions.
11. How does the VICP
protect vaccine administrators and vaccine manufacturers? The
Act requires that vaccine injury claims involving covered vaccines given on or
after October 1, 1988 must first be filed with the VICP before civil litigation
through the tort system can be pursued. If a petitioner accepts an award under
the VICP, the claim cannot be brought subsequently to the tort system.
12. Under what circumstances
may a vaccine administrator or manufacturer be sued?
- If the petition has been
judged non-compensable or dismissed under the VICP; or
-
If the award granted by the VICP is otherwise rejected by the petitioner; or
-
If the vaccine is not covered under the VICP.
13.
Have there been changes to the Vaccine Injury
Table? On
March 10, 1995, a modified Table (and the accompanying Qualifications and Aids
to Interpretation) became effective for all claims filed on or after that date.
Significant changes include the addition of chronic arthritis under vaccines containing
rubella (e.g., MMR, MR, R vaccines), and the removal of Residual Seizure Disorder
and Hypotonic-Hyporesponsive Episode (HHE) under the DTP vaccine. The definition
of Encephalopathy was clarified in the Qualifications and Aids to Interpretation. On
March 24, 1997, further modifications to the Table took
effect that include the addition of brachial neuritis and removal of encephalopathy
for tetanus-containing vaccines, addition of thrombocytopenia and vaccine-strain
measles virus infection, removal of residual seizure disorder for measles-containing
vaccines, and addition of vaccine-strain poliovirus infection for live polio virus
vaccine. Modifications also included the addition of three new vaccines: hepatitis
B, Haemophilus influenzae type b, and varicella. Coverage for these three
new vaccines went into effect August 6, 1997. The Rule also provided for "automatic"
addition of future vaccines recommended by the Centers for Disease Control and
Prevention for routine administration to children, although injuries for such
vaccines will be specified only after additional rulemaking. All other Table changes
became effective for all claims filed on or after March 24. On
October 22, 1998, rotavirus vaccine was added to the Table for coverage. On
August 26, 2002, a modified Table (and the accompanying Qualifications and Aids
to Interpretation) became effective for all claims filed on or after that date.
A second category of rotavirus (live, oral, rhesus-based) vaccine was added to
the Table with intussusception listed as an injury with a time interval of onset
of 0-30 days. A separate category was added for pneumococcal conjugate vaccines
with no condition specified. Haemophilus influenzae type b (Hib) polysaccharide
vaccines was removed from the Table; however, Haemophilus influenzae type b (Hib)
conjugate vaccines remains on the Table with no condition specified. Under the
Table's Qualifications and Aids to Interpretation, early-onset Hib disease and
residual seizure disorder were removed. 14.
What documentation are vaccine administrators required to keep? The
National Childhood Vaccine Injury Act of 1986 (as amended) requires that the date
of administration; vaccine manufacturer; lot number; and name, address, and title
of the health care provider be recorded in the patient's permanent medical record.
15. What adverse events
are health care providers required to report? The
Vaccine Adverse Event Reporting System (VAERS), operated by the Food and Drug
Administration (FDA) and the CDC, should be notified of any adverse event by completing
a VAERS reporting form. The following events are required to be reported:
- Any event set forth in
the Vaccine Injury Table that occurs within the time period specified or within
7 days, if that is longer.
-
Any contraindicating event listed in the manufacturer's package insert.
In
addition, VAERS accepts all reports by any interested party of real or suspected
adverse events occurring after the administration of any vaccine. The
VAERS form may be obtained by calling 1-800-822-7967 or from the FDA Website
at www.fda.gov/cber/vaers/report.htm. Please
note: Submitting a reporting form to VAERS in not the same
as filing a claim under the VICP as they are two separate programs.
16. How many petitions
have been filed under the VICP? Of those petitions filed, how
many have been awarded compensation? How much money has been spent on compensation
awards? To
obtain a copy of the most recent VICP "Monthly Statistics Report" please
visit the VICP Website at www.hrsa.gov/osp/vicp/monthly.htm,
telephone 1-800-338-2382, or write to the National Vaccine Injury Compensation
Program, Parklawn Building, Room 11C-26, 5600 Fishers Lane, Rockville, Maryland
20857. 17.
If I believe that the thimerosal (mercury) in a vaccine caused
an injury or death, can I file a claim with the VICP? For
vaccines covered under the VICP, individuals alleging that the thimerosal in a
vaccine caused an injury or death must first file a claim with the VICP before
any civil litigation can be pursued. According to section 2133 of the Public Health
Service Act (42 U.S.C. 300aa-33(5)), a "vaccine-related injury or death"
eligible for compensation under the VICP does not include an injury or death associated
with an adulterant or contaminant intentionally added to a vaccine. Components,
such as thimerosal, that are added to microorganisms to create vaccines cannot
and should not be considered adulterants or contaminants. Instead, preservatives
and components, such as thimerosal, should be considered one of several elements
that comprise vaccines. Because
thimerosal is not an adulterant to or a contaminant in vaccines, individuals who
have claims relating to thimerosal in vaccines covered under the VICP are not
statutorily barred from filing claims with the VICP. As such, the Department of
Health and Human Services (HHS) believes individuals interested in filing such
a claim must first file the claim with the VICP before pursuing any other civil
litigation. On
October 11, the U.S Court of Federal Claims (the Court) ruled that thimerosal-related
injury claims are subject to the Court's jurisdiction pursuant to the National
Childhood Vaccine Injury Act of 1986, as amended. Plaintiffs had filed a petition
for compensation in the Court, but then filed a motion to challenge the jurisdiction
of the Court for thimerosal-related injuries. The Court found the plaintiff's
arguments to be without merit. As such, the Court's Chief Special Master accepted
HHS's arguments and found that the Court's jurisdiction was mandated on all fronts.
Leroy v. Secretary of HHS is the first definitive statement by the Court
that thimerosal-related vaccine injury claims are subject to its jurisdiction.
For further information on
the "Omnibus Autism Proceeding, visit the Cout's Website at http://www.uscfc.uscourts.gov/osmPage.htm.
18.
Where can I get information about anthrax or smallpox vaccines? Currently,
the anthrax and smallpox vaccines are not covered under the VICP. To obtain information
about these vaccines, contact the National Immunization Program, Centers for Disease
Control and Prevention (CDC) at 1600 Clifton Road, N.E., Mail Stop E-61, Atlanta,
Georgia 30333. You may also contact them at 1-800-232-2522 or visit their Internet
Website at: www.cdc.gov/nip. |